My Policy Hub

Improving health is our policy

  • Dashboard
  • Impact Insights
  • Issues
  • ACA Now
  • Search
  • Contact
  • Dashboard
  • Impact Insights
  • Issues
  • ACA Now
  • Search
  • Contact

ACA Now

3507 - Presentation of Prescription Drug Benefit and Risk Information

 
Implementation Status 
Statutory Text 

Summary

Requires the FDA to evaluate whether use of drug fact boxes in advertising that would more clearly communicate their risks and benefits is warranted.

Implementation Status

 
Summary 
Statutory Text 

FDA has launched a website tracking its analysis mandated under this section.

In October 2013, FDA published on its FDA-TRACK Health Care Reform Dashboard updated information pertaining to completed milestones of the Evaluation of Standardized Risk Benefit Information mandated under this provision of the ACA.

Statutory Text

 
Implementation Status 
Summary 

SEC. 3507 ø21 U.S.C. 352 note¿. PRESENTATION OF PRESCRIPTION DRUG BENEFIT AND RISK INFORMATION. (a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the ‘‘Secretary’’), acting through the Commissioner of Food and Drugs, shall determine whether the addition of quantitative summaries of the benefits and risks of prescription drugs in a standardized format (such as a table or drug facts box) to the promotional labeling or print advertising of such drugs would improve health care decisionmaking by clinicians and patients and consumers. (b) REVIEW AND CONSULTATION.—In making the determination under subsection (a), the Secretary shall review all available scientific evidence and research on decisionmaking and social and cognitive psychology and consult with drug manufacturers, clinicians, patients and consumers, experts in health literacy, representatives of racial and ethnic minorities, and experts in women’s and pediatric health. (c) REPORT.—Not later than 1 year after the date of enactment of this Act, the Secretary shall submit to Congress a report that provides— (1) the determination by the Secretary under subsection (a); and (2) the reasoning and analysis underlying that determination. (d) AUTHORITY.—If the Secretary determines under subsection (a) that the addition of quantitative summaries of the benefits and risks of prescription drugs in a standardized format (such as a table or drug facts box) to the promotional labeling or print advertising of such drugs would improve health care decisionmaking by clinicians and patients and consumers, then the Secretary, not later than 3 years after the date of submission of the report under subsection (c), shall promulgate proposed regulations as necessary to implement such format. (e) CLARIFICATION.—Nothing in this section shall be construed to restrict the existing authorities of the Secretary with respect to benefit and risk information.

Browse ACA Titles

  • I-Quality, Affordable Health Care for all Americans
  • II-Role of Public Programs
  • III-Improving the Quality and Efficiency of Health Care
  • IV-Prevention of Chronic Disease and Improving Public Health
  • V-Health Care Workforce
  • VI-Transparency and Program Integrity
  • VII-Improving Access to Innovative Medical Therapies
  • VIII-Community Living Assistance Services and Supports (CLASS ACT)
  • IX-Revenue Provisions

ABOUT

  • Home
  • About Policy Hub
  • Free Newsletter
  • Team
  • Mission and Values
  • Contact Us

Contact Us

Impact Health Policy Partners 1301 K Street, NW, Suite 300W
Washington, D.C. 20005

(202) 309-0796
Contact Us

Copyright © 2025 ‐ Impact Health Policy Partners ‐ All Rights Reserved ‐ Privacy Policy ‐ Terms and Conditions ‐ Log in